|Publication number||US7427265 B1|
|Application number||US 09/695,748|
|Publication date||Sep 23, 2008|
|Filing date||Oct 24, 2000|
|Priority date||Feb 23, 1998|
|Also published as||EP1056514A1, EP1056514A4, US6231516, US20070112344, US20090005859, WO1999042176A1|
|Publication number||09695748, 695748, US 7427265 B1, US 7427265B1, US-B1-7427265, US7427265 B1, US7427265B1|
|Inventors||George W. Keilman, George E. Cimochowski|
|Original Assignee||Cardiometrix, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (30), Non-Patent Citations (16), Referenced by (15), Classifications (46), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a divisional of pending U.S. patent application Ser. No. 09/028,154, filed Feb. 23, 1998 now U.S. Pat. No. 6,231,516.
This invention relates generally to implantable devices, and, more particularly, to implantable medical devices having therapeutic or diagnostic functions within a lumen of an endoluminal implant such as a stent or other type of endovascular conduit, and methods related to such implantable medical devices.
In the 1970s, the technique of percutaneous transluminal coronary angioplasty (PTCA) was developed for the treatment of atherosclerosis. Atherosclerosis is the build-up of fatty deposits or plaque on the inner walls of a patient's arteries; these lesions decrease the effective size of the artery lumen and limit blood flow through the artery, prospectively causing a myocardial infarction or heart attack if the lesions occur in coronary arteries that supply oxygenated blood to the heart muscles. In the angioplasty procedure, a guide wire is inserted into the femoral artery and is passed through the aorta into the diseased coronary artery. A catheter having a balloon attached to its distal end is advanced along the guide wire to a point where the sclerotic lesions limit blood flow through the coronary artery. The balloon is then inflated, compressing the lesions radially outward against the wall of the artery and substantially increasing the size of its internal lumen, to improve blood circulation through the artery.
Increasingly, stents are being used in place of or in addition to PTCA for treatment of atherosclerosis, with the intent of minimizing the need to repeatedly open an atherosclerotic artery. Although a number of different designs for stents exist in the prior art, all are generally configured as elongate cylindrical structures that are provided in a first state and can assume a second, different state, with the second state having a substantially greater diameter than the first state. A stent is implanted in a patient using an appropriate delivery system for the type of stent being implaced within the patient's arterial system. There are two basic types of stents—those that are expanded radially outward due to the force from an inflated angioplasty type balloon, such as the Palmaz-Schatz stent, the Gianturco-Roubin stent and the Strecker stent, and those that are self expanding, such as the Maass double helix spiral stent, the Nitinol stent (made of nickel titanium memory alloy), the Gianturco stent and the Walistent. Problems with the Maass double helix spiral stent and the Nitinol stent have limited their use.
Stents are sometimes used following a PTCA procedure if the artery is totally occluded or if the lesions have occluded a previously placed surgical graft. Typically, a stent constrained within an introducer sheath is advanced to a site within the patient's artery through a guide catheter. For the balloon expanded type, after the introducer sheath is retracted, a balloon disposed inside the stent is inflated to a pressure ranging from about six to ten atmospheres. The force produced by the inflated balloon expands the stent radially outward beyond its elastic limit, stretching the vessel and compressing the lesion to the inner wall of the vessel. A self expanding stent expands due to spring force following its implacement in the artery, after a restraining sheath is retracted from the compressed stent, or in the case of the Nitinol version, the stent assumes its expanded memory state after being warmed above the transition temperature of the Nitinol alloy (e.g., above 30° C.). Following the expansion process, when the balloon catheter is used, the balloon is removed from inside the stent and the catheter and other delivery apparatus is withdrawn. The lumen through the vessel is then substantially increased, improving blood flow.
After a stent or other endoluminal device is implanted, a clinical examination and either an angiography or an ultrasonic morphological procedure is performed to evaluate the success of the stent emplacement procedure in opening the diseased artery or vessel. These tests are typically repeated periodically, e.g., at six-month intervals, since restenosis of the artery may occur. Due to the nature of the tests, the results of the procedure can only be determined qualitatively, but not quantitatively, with any degree of accuracy or precision. It would clearly be preferable to monitor the flow of blood through the stent after its implacement in a vessel, both immediately following the treatment for the stenosis and thereafter, either periodically or on a continuous basis. Measurements of volumetric rate and/or flow velocity of the blood through the stent would enable a medical practitioner to much more accurately assess the condition of the stent and of the artery in which the stent is implanted. Currently, no prior art mechanism is available that is implantable inside a blood vessel for monitoring blood flow conditions through a stent.
Following stent implantation, it is difficult to monitor the condition of the affected area. Stents often fail after a period of time and for a variety of reasons. Several of the causal mechanisms are amenable to drug treatment. It is highly desirable in at least some of these cases to localize the drug treatment to the site of the graft or surgery. For example, when thrombus forms in a given area, thrombolytic drugs are capable of providing significant assistance in resolving the thrombosis, but may present problems such as hemorrhaging, if they also act in other portions of the patient's body.
The present invention provides a capability for including a therapeutic transducer together with an endoluminal implant such as a stent or stent graft. Therapeutic transducers may include ultrasonic, magnetic, iontophoretic, heating or optical devices, which may permit localized drug delivery or localized drug activation. Provision is made for delivering energy to the implanted transducers and for coupling signals to or from the implanted transducers. The present invention also permits inclusion of diagnostic transducers together with the endoluminal implant and allows signals to be transmitted from the diagnostic transducers to an area outside of the patient's body.
The present invention can allow steps that may be taken to restore full fluid flow through, e.g., a stent that is becoming restricted. In these cases, it is desirable to initiate treatment before the problem proceeds too far to be corrected without stent replacement or further PTCA treatment. Clearly, it would be preferable to be able to monitor the condition of a stent without resorting to invasive surgical procedures and without prescribing medication that may not be necessary, so that the useful life of the stent may be extended, problems associated stent failure avoided and so that medications are only prescribed when required by the known condition of the stent and associated vasculature.
Other advantages that may be realized via embodiments of the present invention including monitoring of other parameters measurable within a stent or other type of endoluminal implant using one or more appropriate sensors or transducers according to embodiments of the present invention. For example, monitoring pressure at the distal and proximal ends of the lumen in the implant and determining the differential pressure can provide an indication of fluid velocity through the lumen. Temperature can also be used to monitor fluid flow by applying heat to the fluid within the lumen and monitoring the rate at which the temperature of the fluid decreases as the fluid flows through the lumen of the implant. Integrated circuit (IC) transducers are currently known and available for sensing the levels of many different types of biochemical substances, such as glucose, potassium, sodium, chloride ions and insulin. Any of these IC sensors could be provided in an endoluminal implant to monitor these parameters.
Since it is impractical to pass a conductor through the wall of an artery or vessel for long periods of time, use of a conventional sensor that produces signals indicative of flow through a stent, which must be conveyed through a conductor that extends through the wall of the vessel and outside the patient's body, is not a practical solution to this problem. Also, any active flow indicative sensor must be energized with electrical power. Again, it is not practical to supply power to such a sensor through any conductor that perforates the vessel wall or that passes outside the patient's body.
In addition to stents, the generic term endoluminal implant encompasses stent grafts, which are also sometimes referred to as “spring grafts.” A stent graft is a combination of a stent and a synthetic graft is endoluminally implanted at a desired point in a vessel. Helically coiled wires comprising the stent are attached to the ends of the synthetic graft and are used to hold the graft in position. Sometimes, hooks are provided on the stent to ensure that the graft remains in the desired position within the vessel. Clearly, it is advantageous to monitor the status of flow and other parameters through a stent graft, just as noted above in regard to a stent.
Endoluminal implants are used in other body passages in addition to blood vessels. For example, they are sometimes used to maintain an open lumen through the urethra, or through the cervix. A stent placed adjacent to an enlarged prostate gland can prevent the prostate from blocking the flow of urine through the urethra. Tracheal and esophageal implants are further examples of endoluminal implants. In these and other uses of endoluminal implants, provision for monitoring parameters related to the status of flow and other conditions in the patient's body is desirable. Information provided by monitoring such parameters, and localized drug delivery or drug activation, can enable more effective medical treatment of a patient through use of embodiments of the present invention.
Another advantage that may be realized through practice of embodiments of the present invention is to be able to activate a therapeutic device on the stent or stent graft that would allow the physician to activate drugs known to be effective in preventing further tissue growth within the stent or stent graft in situations where it is determined that tissue ingrowth is threatening the viability of a stent or stent graft. Again, the therapeutic device should be able to be supplied with electrical power from time to time from a location outside the patient's body.
Yet another advantage that may be realized through practice of the present invention is the treatment of tumors or organs that are downstream of the blood vessel that includes a stent that is coupled to a transducer. The transducer may be remotely activated to facilitate localized drug delivery or to provide other therapeutic benefits.
The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same becomes better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
The present invention is employed for providing therapeutic functions proximate to an endoluminal implant. As used herein and in the claims that follow, the term endoluminal implant broadly encompasses stents, stent grafts (sometimes referred to as “spring grafts”) and other types of devices that are inserted into a lumen or body passage and moved to a desired site to provide a structural benefit to the lumen. To simplify the disclosure of the present invention, most of the following discussion is directed to embodiments comprising a stent.
In one embodiment, parameters are monitored via implanted diagnostic transducers, where the monitored parameters are directed to determining the status of the fluid flow through the endoluminal implant, and therapeutic transducers may be activated in response to the data collected from the implanted diagnostic transducers. For example, the rate or velocity of fluid flow through a body passage in which the stent has been positioned can be monitored to determine the extent of tissue growth or fatty deposits in a blood vessel in which the stent has been implanted to treat atherosclerosis. By monitoring these parameters, which are indicative of blood flow through the lumen of the stent and the blood vessel in which it is implanted, a medical practitioner can evaluate the need for further treatment or determine whether restenosis has occurred, and can locally activate drugs to control restenosis when it is determined to have occurred. This may be possible without additional surgery and without some of the complications associated with systemic administration of drugs. Moreover, other physical and biological parameters can be monitored using one or more appropriate sensors attached to a stent.
When implanted therapeutic transducers are to be activated for an extended period of time or following an extended delay, the stent will likely need to receive electrical power from an external source to energize the implantable electronic circuitry used to activate the implanted therapeutic transducers. Similarly, when the status of fluid flow through a stent that has been implanted in a patient's vascular system (or some other parameter that is sensed proximate the stent) is to be monitored for an extended period or following an extended delay, the implanted circuitry associated with the stent will likely need to receive electrical power from an external source. This power may also be needed to convey data indicating the status of fluid flow (or other parameter) from the implanted stent to a monitoring device that is disposed outside the patient's body. In many cases, it may be desirable to monitor one or more parameters at multiple stents or at multiple locations on a single stent, or to provide therapeutic functions at more than one stent or to multiple locations within or associated with one stent. Thus, the specific transducer employed to provide a therapeutic function or transducer or sensor employed to monitor a desired parameter must be selectable so that the data signal indicating the parameter can be transmitted outside the patient's body. However, in some cases, only a single transducer (which may be operable without any implanted control electronics) may be required to provide a therapeutic function or to monitor a parameter such as fluid volumetric flow or velocity, which is indicative of the internal condition of the stent and of the blood vessel in which it is implanted.
Each of the implantable electronic circuits shown in
Each of the implantable electronic circuits shown in
However, it is also contemplated that the RF-to-DC power supply 32 may provide for a DC-to-DC conversion capability in the event that the electromagnetic signal coupled into the RF coupling coil 30 is too weak to provide the required level of DC voltage for any component. This conversion capability would increase the lower voltage produced by the direct coupling of the external RF excitation signal received by the RF coupling coil 30, to a higher DC voltage. Details of the RF-to-DC power supply 32 are not shown, since such devices are conventional. It is also contemplated that it may be necessary to limit the maximum amplitude of the RF input signal to the RF-to-DC power supply 32 to protect it or so that excessive DC supply voltages are not provided to the other components.
Alternatively, each component that must be provided with a limited DC voltage supply may include a voltage limiting component, such as a zener diode or voltage regulator (neither shown). In another embodiment, the RF coupling coil 30 and the RF-to-DC power supply 32 of
The RF-to-DC power supply 32 may include a battery or a capacitor for storing energy so that it need not be energized when providing a therapeutic function or monitoring the flow status, or at least, should include sufficient storage capability for at least one cycle of receiving energy and transmitting data relating to the parameter being monitored. Neither a battery nor power storage capacitor are illustrated in the Figures, since they are conventional also.
Implantable electronic systems using battery power may only require the ability to receive data and control signals and may include the ability to transmit signals. As a result, they do not necessarily require access to the skin, which access facilitates efficient coupling of power signals. A battery-powered system may result in a very compact implantable system. Alternatively, a battery-powered system that also is capable of recharging the battery via power signals coupled through an implanted coil can permit continuing treatment without requiring that a physician be present throughout the treatment or requiring the patient to be in the medical facility.
An element that is common to each of the implantable electronic circuits shown in
In regard to the implantable electronic circuits shown in
Implantable Electronic Circuits
Referring now to
In addition to ultrasonic transducers 44-46, the implantable electronic circuit shown in
For a single-vessel transit time measurement, a pair of opposed transducers 44-46 that are disposed on opposite sides of the stent are typically used. In order to acquire bi-directional fluid flow data, the direction of the ultrasound wave propagation must be known, i.e., the direction in which the ultrasound wave propagates relative to the direction of fluid flow through the vessel. In this case, the MUX 38 is required. However, for single-vessel applications in which the fluid flow is in a single known direction, the transducers 44-46 that are disposed on opposite sides of the stent can be electrically coupled in parallel or in series, eliminating any requirement for the MUX 38. The RF-to-DC power supply 32 and the RF decode section 40 could also then be eliminated, since the retarded and advanced transit time signals are superimposed on the same RF waveform transmitted by the RF coupling coil 30 to a location outside the patient's body (or outside the blood vessel in which the stent is disposed, if an internal coil is implanted adjacent the blood vessel near where the stent is implanted). Although this modification to the implantable electronic circuit shown in
In some applications, a single transducer 44-46 or group of transducers 44-46 may be employed, in which case the implantable electronic circuit of
When ultrasonic signals are being transmitted by one of the selected transducers 44-46, the TX switch 48 couples the RF excitation signal received by the RF coupling coil 30 to the transducer 44-46 that is transmitting the ultrasonic signal, which is selected by the TX MUX 50. The TX switch 48 is set up to pass excitation signals to the selected transducer 44-46 only if the signals are above a predetermined voltage level, for example, 0.7 volts. Signals below that predetermined voltage level are blocked by the TX switch 48. Similarly, the RX switch 52 couples the transducer 44-46 selected by the RX MUX 54 to the RF coupling coil 30 and passes only signals that are below the predetermined voltage level, blocking signals above that level. Accordingly, the RF signal used to excite a first transducer 44-46 selected by the TX MUX 50 passes through the TX switch 48 and the lower amplitude signal produced by a second transducer 44-46 selected by the RX MUX 54 in response to the ultrasonic signal transmitted through the stent is conveyed through the RX MUX 54 and the RX switch 52 and transmitted outside the patient's body through the RF coupling coil 30.
The implantable electronic circuit shown in
In contrast to the implantable electronic circuits shown in
The control signals that are supplied to the RF decode/control section 66 via the RF coupling coil 30 can be conveyed using nearly any kind of modulation scheme, e.g., by modulating the RF excitation that powers the device, or by sending a control signal on a separate and distinct RF frequency. Also, the signals that are received from the transducer 44-46 in response to the ultrasonic wave that is propagated through the stent can be transmitted through the RF coupling coil 30 at a different frequency than the incoming excitation frequency, thereby reducing the likelihood of interference between the power supply and data signal transmission functions.
The implantable electronic circuit shown in
To further improve the implantable electronic circuit shown in
It is also contemplated that the RF decode/control section 66 may cause the MUX 38 to select a different transducer 44-46 for producing/receiving the ultrasonic waves after a predefined number of transmit/receive cycles have elapsed. For example, a different transducer 44-46 may be selected after eight cycles have been implemented to transmit an ultrasonic wave into the stent and to receive back the echoes from the fluid flowing through the stent. By collecting data related to the status of flow through a stent in this manner, it becomes unnecessary to send programming information to the RF decode/control section 66 after each cycle of a transmission of the ultrasonic wave into the fluid in the stent and reception of the echo. Also, by carrying out a predefined number of transmit/receive cycles for the given transducer 44-46 that has been selected by the MUX 38 and averaging the results, a more accurate estimate of fluid velocity through the stent can be obtained than by using only a single transmission and reception of an ultrasonic wave. Since the signal required to instruct the RF decode/control section 66 to change to the next transducer 44-46 is only required after the predefined number of cycles has been completed, the data gathering efficiency of the implantable electronic circuit is improved.
As noted above, the transducers 44-46 shown in
RF Coupling Coil and External Coil Embodiments
One method for optimizing coupling between an implanted coil and a coil that is external to the body is described in High-Efficiency Coupling-Insensitive Transcutaneous Power And Data Transmission Via An Inductive Link by C. M. Zierhofer and E. S. Hochmair, IEEE Trans. Biomed. Eng., Vol. 37, No. 7, July 1990, pp. 716-722. This approach allows the frequency of the signal linking the implanted and external coils to vary in response to the degree of coupling between the two coils. Other methods are suitable for coupling signals between the two coils as well.
When the implantable electronic circuit includes the RF coupling coil 30 and a transducer 44-46, but does not include active electronic circuitry, the external system (e.g., external power supply and patient monitoring console 100,
The implantable electronic circuit may include an additional component to facilitate sensing of alignment between the two coils. For example, a metal disc in the implant may be detected and localized by inducing an eddy current in the disc. The external power supply and patient monitoring console may then detect the magnetic field generated by the eddy current in the disc, much as a metal detector operates. Using different frequencies for the location and therapeutic functions may avoid energy losses caused by the eddy currents.
When the implantable electronic circuitry does include active electronic circuitry, a circuit may be included with the therapeutic transducer and RF coupling coil that measures the amplitude of the signal from the external power supply and patient monitoring console that is induced in the RF coupling coil. A signal is transmitted from the implantable electronic circuitry to the external power supply and patient monitoring console, where a display provides an indication of the coupling. The operator may adjust the position of the external coil to optimize coupling between the two coils.
The penetration of RF fields in the human body has been studied extensively in conjunction with magnetic resonance imaging (MRI) systems. RF attenuation increases with frequency, but frequencies as high as 63 MHz are routinely used for whole-body imaging, although some attenuation is observed at the center of the torso at this upper frequency limit. In addition, MRI safety studies have also provided a basis for determining safe operating limits for the RF excitation that define the amplitude of excitation safely applied without harm to the patient.
It is contemplated that for stent implants placed deep within the torso of a patient, RF excitation and frequencies used for communicating data related to the fluid flow through a stent and/or other parameters sensed proximate the stent can be up to about 40 MHz, although higher frequencies up to as much as 100 MHz may be feasible. At 40 MHz, the wavelength of the RF excitation signal in tissue is about 82 cm, which is just that point where wavelength considerations become an important consideration. For shallow implants, RF excitation at a much higher frequency may be feasible. For example, to provide energy to stents that are disposed within a blood vessel only a few millimeters below the epidermis and to receive data from transducers associated with such stents, excitation frequencies in the range of a few hundred MHz may be useful. The dielectric properties of tissue have been studied to at least 10 GHz by R. Pethig, Dielectric and Electronic Properties of Biological Materials, Wiley Press, Chichester, 1979 (Chapter 7). Based on this study, no penetration problems are anticipated in the frequency range of interest. The relative dielectric constant of tissue decreases to about 60 at a frequency of 100 MHz and is about 50 at 1 GHz, but this parameter has little effect on power/data signal coupling.
An external coil 90 and a RF coupling coil 30A shown in
Although the external coil 90 and the RF coupling coil 30A need not be identical in size, it is generally true that coupling will be optimal if the two devices are of approximately the same dimensions and if the longitudinal axis of the external coil 90 is generally adjacent and parallel to that of the RF coupling coil 30A. By observing the strength of the signal transmitted from the RF coupling coil 30A, it should be possible to position the external coil 90 in proper alignment with the RF coupling coil 30A so that the efficiency of the magnetic coupling between the two is optimized.
To function as the core 94 for the external coil 90, the material used should have a relatively high magnetic permeability, at least greater than one. Although ferrite is commonly used for core materials, sintered powdered iron and other alloys can also be used. Since the magnetic characteristics of such materials are generally conventional, further details of the external coil 90 and the core 94 are not provided.
A housing 96 on the external coil 90 provides RF shielding against electromagnetic interference (EMI). In one embodiment, the housing 96 for the external coil 90 is conductive, grounded and surrounds the external coil 90 except where the surfaces of the generally “C-shaped” core 94 are opposite the RF coupling coil 30A. The RF shield comprising the housing 96 is attached to an internal braided shield 99 of the cable 98. Inside the power supply and patient monitoring console (not shown in
For the embodiment shown in
The RF coupling coil 30A used in the stent 106 may be either an integral part of the stent 106, or it may instead comprise a separate RF coupling coil 30A that is wound around or through the structure comprising the wall of the stent 106. To function within the body of a patient, the stent 106 must be able to bend and flex with movement of the body, yet must have sufficient surface area and hoop strength to compress the atheriosclerotic material that is inside the blood vessel wall radially outward and to support the vessel wall, maintaining the lumen cross section. Several manufacturers offer stent designs, each fabricated from wire, bent back and forth in a periodically repeating “S” shape or zigzag configuration, forming a generally cylindrical tube. Such stents are considered ideal for use in practicing the present invention, since the wire comprising the wall of the stent 106 can be used for the RF coupling coil 30A. Examples of such stents are the ANGIOSTENT stent made by AngioDynamics, the stent sold by Cordis Corporation, the CARDIOCOIL stent produced by Instent and the WIKTOR stent from Medtronic Corporation.
Stents comprising a woven mesh of fine helical wires are available from certain stent manufacturers. The woven mesh provides the required hoop strength needed to support the wall of a blood vessel after the stent is implanted and expanded or allowed to expand. To maintain the required flexibility for the stent, the wires comprising the woven mesh of such stents are not joined at the intersection points. An example is the WALLSTENT stent, which is sold by Medivent-Schneider. This configuration is also well suited for practicing the present invention. To be used as the RF coupling coil 30B, the wires forming the body or wall of the stent 106A must be electrically insulated from the surrounding tissue of the blood vessel 107 and must be insulated from each other where they cross except at any node wherein the helical turns are linked to form one or more sets of coupled turns. The wire used for this configuration can be either round or flat.
An embodiment of a RF coupling coil 30C comprising a stent 106B is shown in
The couplings at the nodes 134 are preferably not made randomly or in a haphazard fashion between the various wires comprising the woven mesh 132. A first wire comprising a helical coil having, e.g., a first configuration (which may be called a “right hand spiral” or RHS) has a first end coupled to a first end of a second wire comprising a helical coil having a second configuration (“left hand spiral” or LHS; i.e., a mirror image of the right hand spiral). The voltage induced in the two wires is equal, but opposite in sign, and the two wires are thus coupled in series and provide twice the voltage between their second ends than that produced between the first and second ends of either wire alone. Accordingly, the second ends of the first two wires cannot be coupled together at the other end of the woven mesh 132 if these two wires are to contribute to the total electrical energy derived from the woven mesh 132. Rather, the wires must be “daisy chained” in series (i.e., RHS-LHS-RHS-LHS etc.) to provide one embodiment of the RF coupling coil 30C. Alternatively, a first group of wires all having the right hand spiral may all be coupled in parallel (i.e., have the ends at a first end of the woven mesh 132 coupled together, and the ends at a second end of the woven mesh 132 coupled together), with wires having the left hand spiral being similarly treated but in a second group. The groups then may be combined in series or in parallel, or subsets of the wires may be grouped and combined.
When each wire comprising the woven mesh 132 passes around the central axis of the stent 106B through m degrees, and if there are a total of n such wires, then the equivalent number of turns in the RF coupling coil 30C is equal to n×m÷360. Leads 136 and 138 convey signals to and from the nodes 134, coupling the woven mesh 132 to the implantable electronic circuit 110, which may comprise any of the implantable electronic circuits of
The woven mesh structure of the implantable RF coupling coil 30C is often used for stents. However, it should be noted that currently available woven mesh stents are not woven from insulated wire, nor are the nodes of the mesh at each end electrically connected in commercially available stents. In the WALLSTENT stent by Medivent-Schneider, the ends are instead free floating. It is also contemplated that an insulated electrical conductor could be woven into the structure of a commercially available mesh stent. Alternatively, the RF coupling coil 30C could be fabricated from a woven mesh or from a plurality of spiral turns of a conductor and then the mechanical characteristics required of the stent could be achieved by providing an interwoven wire within the RF coupling coil 30C. It is also noted that different implantable electronic circuits can be coupled to separate portions of the woven mesh 132 comprising the RF coupling coil 30C so that the different portions of the RF coupling coil 30C and the implantable electronic circuits are electrically isolated from each other, or as a further alternative, the sections can be coupled in series.
For use in electromagnetically coupling with the RF coupling coil 30D to energize the implantable electronic circuit 110 and to provide signals to and receive data from the transducers 44-46 (not separately shown) on the stent 106C, an external coil 90B is provided that includes a plurality of coils 92B wrapped around a central portion of a generally E-shaped core 94B. Lines of electromagnetic flux 112 are thus produced between the central leg and each of the end legs of the core 94B. It will therefore be apparent that this embodiment of the RF coupling coil 30D and of the external coil 90B achieves optimum coupling when the distance separating the two is minimal. Therefore, the RF coupling coil 30D and the external coil 90B are best used in applications where the stent 106C is disposed relatively close to the dermal layer 102 so that tissue 104 separating the stent 106C from the external coil 90B is only a few centimeters thick. Maximal coupling is achieved when the central axis of the external coil 90B is aligned with the central axis of the coil mounted on the stent 106C.
The metal tube 116 includes a plurality of generally longitudinally extending slots 117 at spaced-apart locations around the circumference of the stent. These slots 117 provide the expansibility and flexibility required of the stent. This design is similar to the Palmaz-Schatz stent made by Johnson & Johnson Corporation. To avoid providing a shorted turn with the body of the metal tube 116, the generally conventional design of the stent is modified to include a break 118 extending along the entire length of the metal tube 116. The edges of the metal tube 116 are coupled at several joints 119 along the break 118 using a non-conductive material.
Metal-to-ceramic (or metal-to-glass) welded joints 119 are commonly employed in medical implants and other electrical devices. To minimize thermal stress in the joint 119, the metal and the glass or ceramic must have similar thermal expansion coefficients. For example, KOVAR™ alloy, a nickel-iron alloy (29% Ni, 17% Co, 0.3% Mn and the balance Fe) is one material that can be used to form glass to metal seals that can be thermally cycled without damage. This material can be used to form portions of the metal tube 116 disposed along the break 118. Glass or ceramic bonds comprising the joints 119 then will not experience much thermal stress when the temperature of the stent changes. This material is commonly used in lids that are bonded onto ceramic chip carriers in the integrated circuit industry and thus is readily available.
An alternative design for a stent formed from a non-woven wire 145 about which the RF coupling coil 121 is coiled is illustrated in
In those cases where stents are implanted relatively deeply inside the patient's body, at some distance from the surface of the patient's skin, an alternative external coil 154 can be employed, generally as shown in
Description of the Diagnostic Applications of Transducers
An ultrasonic transducer for monitoring flow or fluid velocity through a stent should be relatively compact and included in or mounted on the wall of a stent. Typical prior art ultrasonic transducers include a planar slab of a piezoelectric material having conductive electrodes disposed on opposite sides thereof. Since such elements are planar, they do not conform to the circular cross-sectional shape of a stent. Moreover, prior art transducers are not compatible for use with a stent that is implanted within a patient's body and which is intended to be left in place for an extended period of time. Also, it is apparent that conventional ultrasonic transducer elements will not readily yield to being deformed into a compact state for implacement within a blood vessel, followed by expansion of a stent body to apply radially outwardly directed force to compress the deposits within a blood vessel.
When used for transit time measurements, as shown in
The conformal transducer arrays 174A and 174B shown in
In the case of pulsed Doppler velocity measurements, a single conformal transducer array 174A would again likely be adequate so long as the alignment of the conformal transducer array 174A to the stent 168 is accurately controlled. If the alignment of the conformal array transducer 174A is not controlled or not well known, a second such conformal transducer array 174B can be used to gather velocity data along a second beam axis using pulsed Doppler velocity measurements. Assuming that the second axis is tilted in an equal but opposite direction as the first axis, the Doppler measurements made by the two conformal transducer arrays 174A and 174B should be self-compensating for tilt errors. In this case, the second conformal transducer array 174B could be mounted on the same or on an opposite side of the stent from that where the first conformal transducer array 174A is mounted to implement the Doppler measurements.
For CW or pseudo-CW Doppler velocity measurements (in which a relatively long duration pulse of ultrasonic waves is produced), the transit signal is applied for a sufficiently long period so that a second conformal transducer array 174B is needed to receive the echo signals. In this case, a single set of diametrically opposed conformal transducer arrays 174A and 174B can be used.
As perhaps best illustrated in
To produce a wide, uniform ultrasonic beam such as that needed for transit time measurements of flow, the conformal transducer arrays 174A and 174B must produce ultrasonic waves having a wave front characterized by a substantially uniform amplitude and phase. As shown in
Projected Spacing in millimeters=1.54/(4*F 0),
where F0 is equal to the center frequency in MHz. If zero degrees is assigned to the top-most element of the conformal transducer array 174A, the next element would operate at −90° relative to the top element, followed by an element operating at −180°, and then one operating at −270°, and finally by an element operating at 0° relative to the top electrode. Thus, the conformal transducer array 174A produces a succession of ultrasonic waves spaced apart by a 90° phase shift, thereby achieving a desired phase uniformity across the conformal transducer array 174A.
While the discussion herein is in terms of phase shifts of 900, it will be appreciated that other types of transducer element spacings or relative displacements may require different phase shifts. For example, three phase transducers are known that employ a phase shift of 120° between adjacent elements. Additionally, physical displacements of the transducer elements in the direction of propagation of the acoustic waves may require different or additional phase shifts between the electrical signals coupled to the elements. It is possible to phase shift these signals to provide a uniform phase front in the propagating acoustic wave using conventional techniques.
Amplitude uniformity can be achieved in the ultrasonic wave front by apodization or “shaving” of the elements of the conformal transducer arrays 174A and 174B. Although shaving could be achieved in a variety of ways, one embodiment controls shaving by varying the area of each element.
In one embodiment, the conformal transducer arrays 174A and 174B are carried on a band 172 made from the piezoelectric plastic material used for the element substrate, which is sized to fit snugly around an outer surface of the stent 168 or inserted into the lumen of the stent 168 (as shown in
Referring now to
The pattern of elements comprising each of the conformal transducer arrays 174A and 174B and the boundary of each conformal transducer array 174A and 174B (top and bottom as shown in
Similarly, the amplitude of the sinusoidal segment defining the boundary of each conformal array 174A and 174B is defined by:
where Θ is equal to the angle between the longitudinal axis of the stent 168 (see
The conductors 180 that couple to adjacent transducer elements differ in phase by 90°. There are two ways to achieve the 90° phase variation between the ultrasonic waves produced by successive electrodes in the conformal transducer arrays 174A and 174B. In the first approach, a uniformly polarized piezoelectric plastic substrate is used and every fourth element is coupled together, producing four groups of elements or electrodes that produce ultrasonic waves having phase relationships of 0°, 90°, 180° and 270°, respectively. Alternatively, a zone polarized piezoelectric plastic substrate could be used and every other element can be coupled together (as shown in
In the second approach, which may be preferred in some embodiments because it may simplify the electronic package required and because it may facilitate use of a simpler, double-sided electrode pattern, the piezoelectric plastic material must be locally poled in a specific direction, depending upon the desired phase of the electrode at that location. A poling direction reversal provides a 180° phase shift, eliminating the need for 180° and 270° phase-shifted signals. Thus, the zones of the substrate designated as 0° and 90° would be connected to the in-phase and quadrature signal sources with the elements poled in one direction, while zones for elements designated to provide a relative phase shift of 180° and 270° would be connected to the in-phase and quadrature signal sources with the elements poled in the opposite direction. The elements producing ultrasonic waves with a relative phase relationship of 0° and 180° would comprise one group (e.g., in-phase) and the elements producing ultrasonic waves with a relative phase relationship of 90° and 270° would comprise a second group (e.g., quadrature). Poling the different groups of elements in local regions in opposite directions is achieved by heating the material above the Curie temperature, applying electric fields of the desired polarities to each of those areas and then cooling the material below the Curie temperature while maintaining the electric fields. This occurs during manufacture of the conformal transducer arrays 174A and 174B. The final element wiring pattern required to actually energize the conformal transducer arrays 174A and 174B when they are employed for monitoring flow and/or velocity of fluid through the vessel 170 would preclude applying electric fields in opposite polarity. Accordingly, the required poling relationship would have to be performed using either temporary electrodes or by providing temporary breaks in the actual electrode pattern employed in the final conformal transducer arrays 174A and 174B.
In one embodiment, to achieve a desired frequency of operation, it is contemplated that the electrode mass would be increased to a point well beyond that required for making electrical connections. This added mass would act together with the piezoelectric plastic material to form a physically resonant system at a desired frequency. In this manner, a relatively thinner and more flexible piezoelectric plastic material can be used for the substrate comprising the band 172. Use of mass loading is conventional in the art of ultrasonic transducer design.
While the fluids within the vessel 170 may provide an effective ground plane, in one embodiment, a conductive layer 177 (see
In the embodiment illustrated in
The interaction of the blood with the ultrasound, even when it is moving at constant velocity, gives rise to a moving acoustic “speckle” pattern. The term speckle, as used herein, has a similar meaning in ultrasonics as in optics. It results any time that narrow-band illumination is used. Optical speckle is visible when a laser (e.g., a pointer) illuminates a plain white wall. When illuminated with wideband illumination, the wall appears white and smooth. When illuminated with laser light, the wall appears to have bright and dark spots, hence the term speckle. Acoustic speckle is visible in medical ultrasound images, when the system is used to image homogeneous soft tissues such as the liver. As in optics, the acoustic speckle pattern is stationary and constant unless the tisse or flood is moving with respect to the imaging system. The same phenomenon is exploited in Doppler systems. When the echo return from moving blood is constant, there is no observable Doppler shift in the echo signal.
The blood consists of thousands of scatterers, and the ultrasound reflects from ensembles of these scatterers. The amplitude and phase of the echo, at a given range, depends on the local distribution of scatterers, which is random. The random signal of echo amplitude and phase at a given depth repeats as the blood flows past the second ultrasonic transducer 242B, if the spacing between the two ultrasonic transducers 242A and 242B is such that the ensembles of scatterers have not changed significantly, i.e., if the two ultrasonic transducers 242A and 242B are close enough to each other that turbulence has not significantly disrupted the ensembles of scatterers. Correlation of nominally identical random patterns that are displaced in time by an amount equal to the time required for the blood to move from the first beam to the second one allows the velocity to be determined when the separation between the two ultrasonic transducers 242A and 242B is known.
In other words, the first ultrasonic transducer 242A receives an echo signal that provides a speckle “image”—where the distance from the ultrasonic transducer 242A is along the vertical dimension in
The sampling aperture for this system is much shorter than the time required for a heartbeat. Accordingly, a series of measurements, which may be taken during the interval between two successive heartbeats, may be processed or compared to determine peak, minimum and average blood velocity when these data are desired.
Unlike a Doppler system, the echoes in a correlation type transducer system like that shown in
The conformal transducer arrays 174A and 174B of
In one embodiment, the acoustic backing 194 comprises one volume of EPOTEK 377 or 301-2 epoxy glue available from Epoxy Technology of Billerica, Mass. mixed, e.g., with two or more volumes of microballoons available from PQ Corp. of Parsippany, N.J. Microbubbles such as PM6545 acrylic balloons having an average diameter of 100 microns are employed in one embodiment, with the acoustic backing being 10 to 20 microballoons thick (one to two mm). The acoustic backing 194 has a relatively low dielectric constant (e.g., <10), thereby minimizing capacitive loading between the electrodes and surrounding tissue. The acoustic backing 194 thus insulates the transducer elements from the surrounding fluid and tissue in a capacitive sense and also in an acoustic sense. The next layer comprises a rear electrode 196. A front electrode 200 is spaced apart from the rear electrode by a piezoelectric plastic layer 198. In one embodiment, the front electrode 200 is also the conductive layer 177 of
In one embodiment, the rear electrode 196 and the front electrode 200 comprise multi-layer structures (although separate layers are not shown). For example, the electrodes 196 and 200 will include a metallic layer that bonds well to the piezoelectric plastic layer 198, for example, titanium, followed by a highly conductive layer, for example, copper, followed by an oxidation resistant layer, for example, gold, and includes other metallic barrier layers, where appropriate, to prevent reaction between these layers. Such multi-layer systems are conventional and are suited for use as the electrodes 196 and 200 in the conformal transducer arrays 174A and 174B.
In one embodiment, the front electrode 200 is the “common electrode” for the transducer elements and serves as a RF shield. A front coating 202 serves as an acoustic coupling between the conformal transducer arrays 174A and 174B and the fluid in the lumen of the stent. In addition, the front coating layer 202 serves as a biocompatible layer, providing a barrier to fluid ingress into the conformal array transducers 174A and 174B.
In both the conformal array transducers 174A and 174B provided in the band 172 (as shown in
As noted above, one of the advantages of the conformal transducer arrays 174A and 174B is a relatively low profile. In some cases, a stent may integrally accommodate a relatively thicker profile transducer assembly. An embodiment of a tilted element transducer 210 coupled to a stent 203 that is useful as a diagnostic transducer or as a therapeutic transducer is illustrated in
An outer coating 195 again serves the function of providing a biocompatible layer to protect the transducer components contained therein from exposure to bodily fluids. When the outer coating 195 comprises PARYLENE alone, an RF shield 193 extends over the tilted elements, immediately inside the outer coating 195. When the outer coating 195 comprises a container (as illustrated), it includes an outer coating of a material such as PARYLENE. When the outer coating 195 comprises a conductive material, a separate RF shield such as the RF shield 193 may not be required. The acoustic backing 194 is disposed below the RF shield 193 or the outer coating 195.
An acoustic filler material 212 is disposed between the front electrode 200 and the front coating 202, on the interior surface of the stent 203, and is used to fill in the cavities in front of the transducer elements. The acoustic filler material 212 is characterized by a relatively low ultrasonic attenuation, so that it readily conveys the ultrasonic waves produced by the transducer elements into the lumen of the stent 203. In one embodiment, in order to minimize reverberations of the ultrasonic waves in this acoustic filler material 212, its acoustic impedance, which is related to sound velocity times density, is approximately equal to that of the fluid in the vessel. The velocity of sound in the acoustic filler material 212 should also be close to that of the fluid flowing through the stent 203 so that the sound beam is not significantly deflected by the acoustic filler material 212. In another embodiment, the acoustic filler material 212 has a relatively low sound velocity compared to the fluid. In this embodiment, the acoustic filler material 212 acts as an acoustic lens that deflects the sound being produced by the elements of the tilted element transducer 210. For example, materials such as silicones or fluorosilicones typically having sound velocities about 1000 meters per second (compared to a sound velocity of approximately 1540 meters per second for blood) may be used. Low velocity lenses are conventional. A benefit of using a low velocity acoustic filler material 212 is that the elements of the tilted element transducer 210 can be tilted about 30% less than would be required otherwise. As a result, the overall height of the tilted element transducer 210 portion of the stent 203 can be made about 30% thinner than would be possible without the low velocity acoustic filler material 212. In combination, the plurality of tilted elements of the tilted element transducer 210 produce an ultrasonic wave 214 that propagates at an angle relative to the longitudinal axis of the stent, which is represented by a center line 216 in
It is contemplated that the implantable IC transducer 220 might be used for measuring parameters such as pressure, temperature, blood gas concentration and insulin level or the levels of other metabolite such as glucose or sodium in the blood stream of a patient in which a stent that includes the IC sensor 220 is implanted. As explained above, the implantable IC sensor 220 is electrically energized with electrical power that is electromagnetically coupled to the RF coupling coil 223A that comprises the stent body 222A or which is incorporated as one or more separate insulated windings within the stent wall structure. Signals produced by the IC sensor 220 are converted to data signals, which are electromagnetically coupled to a monitor outside the patient's body, also as explained above. In certain applications of implantable IC sensors 220, it may be advantageous to perform a differential measurement between two spaced-apart locations on the stent body 222 or 222A. Thus, to monitor fluid flow through the lumen of a stent 222 or 222A, a differential pressure measurement made by transducers respectively disposed adjacent the proximal and distal ends of the stent 222 or 222A provide an indication of blood flow and of any blockage with the lumen of the stent 222 or 222A.
If an external source of heat is applied to heat the blood or other fluid flowing through the lumen of a stent 222 or 222A, flow can be determined by monitoring the temperature of the fluid with IC sensors 220 that are responsive to that parameter. An external source of RF energy electromagnetically coupled into the stent 222 or 222A, as disclosed above, can both provide the electrical power for the components of the stent transducer system and provide the power for heating the fluid. To avoid tissue damage, the maximum stent temperature should remain below 42.5° C., which is well established as the temperature above which hyperthermia and irreversible tissue damage occur. By analyzing the resultant temperature vs. time “thermal washout” curve, the flow rate of fluid through the stent 222 or 222A can be determined. A differential temperature measurement made by temperature sensors disposed adjacent the opposite ends of the stent 222 or 222A could also be used to determine flow through the stent lumen. Using the signals from these sensors, two temperature vs. time curves can be developed simultaneously. Differences in the observed thermal washout curves should be primarily a function of flow through the lumen and thus indicative of that parameter.
Other methods can be employed to determine flow based on temperature measurements. For example, by modulating the RF power used to heat the stent 222 or 222A, the temperature vs. time curves will exhibit the modulation frequency. The temperature vs. time curves produced by spaced-apart temperature sensors can be filtered with a relatively narrow bandwidth filter. The phases of the two filtered signals are compared to extract a flow velocity through the stent 222 or 222A. The signal processing concept of this approach is conceptually similar to that used for measuring cardiac output using a catheter-mounted heater and temperature sensors, as disclosed in U.S. Pat. No. 5,277,191 entitled Heated Catheter For Monitoring Cardiac Output.
Several types of IC sensors 220 that might be incorporated within a stent in accord with the present invention are disclosed in previously issued U.S. patents. For example, U.S. Pat. No. 4,020,830 (and re-examination certificate B1 U.S. Pat. No. 4,020,830) entitled Selective Chemical Sensitive FET Transducers and U.S. Pat. No. 4,218,298 entitled Selective Chemical Sensitive FET Transducer describe chemical field effect transistor (FET) transducers that are sensitive to specific chemical substances or to their properties. U.S. Pat. No. 4,935,345 entitled Implantable Microelectronic Biochemical Sensor Incorporating Thin Film Thermopile discloses an implantable microelectronic biochemical sensor that incorporates a thin film thermopile for use in monitoring concentrations of glucose or other chemicals present in the blood stream. Various types of pressure sensing devices appropriate for incorporation in the wall of a graft are readily available from a number of different commercial sources, including SRI Center for Medical Technology of Palo Alto, Calif.
Other prior art devices are potential candidates for use as IC sensors 220 on stents 222 or 222A. In Evaluation of a Novel Point-of-Care System, the I-Stat Portable Clinical Analyzer, CLINICAL CHEMISTRY, Vol. 39, No. 2, 1993, K. A. Erickson et al. describe a blood analyzer based on disposable IC biosensors that can quantify sodium, potassium, chloride, urea, nitrogen and glucose levels. A good overview of acoustic wave biosensors is provided by J. C. Andle et al. in Acoustic Wave Biosensors, published in the 1995 IEEE Ultrasonics Symposium Proceedings, IEEE cat. no. 0-7803-2940-6/95, pp. 451-460. Other types of IC biosensors are described in the art. However, it is sufficient for this disclosure to recognize that such IC sensors 220 are well known in the art and are generally available or readily fabricated for use on stents 222 or 222A (or other stent designs) as described above.
In the embodiments of
A stent may include other types of sensors beside the ultrasonic transducers and the IC sensor 220 noted above.
In another embodiment, the sensing filaments 234 may be spatially more limited to allow assessment of where blockage is occurring within the stent 232. A plurality of localized sensing filaments 234 may permit assessment of more than one area within the stent 232, by taking a series of measurements and communicating the results of the series of measurements to the attending physician. This may provide data relevant to determining what form of treatment is appropriate.
For measuring the dielectric properties, the implantable IC sensor 220B is energized with power electromagnetically coupled from an external source into the RF coupling coil (not illustrated in
6 to 20
2000 to 3000
80 to 160
80 to 90
60 to 130
100 to 150
The permittivity of tissue is closely related to its water content. Water has a relative permittivity of about 80. Since fat and fatty deposits of the type found inside blood vessels contain much less water than other tissue types, the permittivity of fat is much lower than that of muscle or blood. The wall of a blood vessel is muscular and highly perfused and will therefore have a much higher permittivity than a fatty deposit. Similarly, fatty deposits have a much higher resistivity than either blood or muscle. Therefore, a measurement of the dielectric and/or resistive properties of tissue inside the stent 232 can differentiate fatty deposits from either blood or muscular tissue ingrowth into the lumen. The measurement can include a determination of capacitance, resistance or a combination of the two.
Further information can be obtained from the frequency dependence of the capacitance and resistance measured inside a stent lumen. For example, blood has a relatively flat resistivity vs. frequency characteristic curve, compared to that of muscle.
The stent graft 260 is of a type that is used to repair arteries near a bifurcation of the artery into two small branches 268 and 270. However, it should be noted that the present invention can be used with almost any type of stent graft and is not in any way limited to the bifurcated type shown in the figure. The TALENT spring graft system available from World Medical Manufacturing is similar to the stent graft 260. The term “spring graft” is used with this type of stent graft 260 because the stent portions 262 and 266 may be self-expanding, comprising Nitinol springs acting as stents 262 and 266 that are embedded into polyester (DACRON™) or PTFE synthetic graft section 264. The larger diameter aortic section typically comprises DACRON and the smaller branch portions typically comprise PTFE. The material comprising the synthetic graft section 264 is stitched to the Nitinol stents 262. Although a Nitinol stent is normally self-expanding, a balloon (not shown) may be included in the delivery system to perform one or more functions, including expansion of the stent 262, placement at the desired location, flow occlusion and straightening blood vessels to aid advancement of the assembly to the desired location. Electrically insulating ceramic joints 276 couple sections of each stent 262 and 266 to break any current loop that could reduce the efficiency of the RF coupling coil. An insulated wire 272 is wound around the outside of the graft 264 and, in one embodiment, is formed of kinked or zigzag wire to enable expansion of the graft 264. The wire 272 is coupled to a sensor/electronic circuit 274. Stent grafts suitable for use in the embodiment shown in
Description of Therapeutic Transducers
A variety of therapeutic transducers may be implanted that are responsive to and/or powered by the signals coupled into the implantable electronic circuits of
In adjunctive therapy, the therapeutic transducer is intended to realize localized drug activation and delivery in the vicinity of the stent or stent graft. This could be to maintain flow capability through the lumen by reducing restenosis due to new deposits of atherosclerotic material or to inhibit tissue ingrowth. Alternatively, in at least some cases, the same therapeutic transducer may aid in reducing thrombosis that is causing lumen blockage by activating appropriate drugs.
In primary therapy, the stent with the therapeutic transducer is implanted specifically to provide local drug activation and delivery to tissue in the vicinity of and downstream from the stent. For example, a stent could be implanted in an artery that feeds blood to a tumor site. Systemically administered chemotherapeutic agents that are not toxic until activated may be activated during passage through the stent by energy provided by the therapeutic transducer. The blood containing the activated drug then proceeds downstream to the tumor site to locally administer the activated drug. This approach can provide significantly greater drug concentrations at the tumor site than are obtained systemically. Similarly, other drugs used to treat a variety of diseases may be locally activated at the region of interest. In some cases, modified genetic material may be locally concentrated in response to therapeutic transducer activation.
One advantage to localized activation or delivery of drugs is that the side effects associated with the drugs may be reduced by only providing the drug at the site requiring treatment. This is advantageous in many situations, including chemotherapy, where the drugs are toxic or may have other potentially detrimental side effects.
For example, drug activation phenomena have been reported using ultrasound to break precursor substances down into drug molecules and other by-products. In this case, one or more of the transducers 44-46 of
Sonodynamic activation at one or more specific body sites to provide local drug delivery is possible when one or more of the transducers 44-46 of
The stent 279 includes an implantable ultrasonic transducer 280 on a first surface and a device 282 on a second surface. The device 282 may be either another ultrasonic transducer similar to the transducer 280 or an acoustic reflector. The ultrasonic transducer 280 may be coupled to implantable electronic circuits using any of the approaches described in connection with
The piezoelectric material forming the transducer 280 may comprise piezoelectric plastic materials such as PVDF, P(VCN/VAc) or P(VDF-TrFE), available from AMP Sensors of Valley Forge, Pa., or any of the piezoelectric ceramics, e.g., lead zirconium titanate. In one embodiment, PZT-4 material available from Morgan-Matroc of Bedford, Ohio provides high electroacoustic coupling and low acoustic losses. In another embodiment, the piezoelectric plastic P(VDF-TrFE) provides high electroacoustic coupling and low acoustic losses.
The transducer 280 (and, when the device 282 is a transducer, the device 282) may be of the type described, for example, with respect to
When the device 282 is chosen to be an acoustic reflector, either a low impedance reflector (i.e., providing an acoustic reflection coefficient approaching −1) or a high impedance reflector (i.e., providing an acoustic reflection coefficient approaching +1) may be employed. Low-density foams (e.g., analogous to the acoustic backing material 194 of
Alternatively, methods for localized delivery of medication include encapsulation of medications in delivery vehicles such as microbubbles, microspheres or microballoons, which may be ruptured to locally release the medications via localized energy provided by implanted transducers. In some embodiments, the delivery vehicles may include magnetic material, permitting the delivery vehicles to be localized via an applied magnetic field, as described in U.S. Pat. No. 4,331,654 entitled Magnetically-Localizable, Biodegradable Lipid Microspheres.
In one embodiment, the device 282 is formed from a magnetic ceramic or a magnetic metal alloy, and is also capable of acting as an efficient acoustic reflector. This embodiment allows localization of magnetic delivery vehicles via the static magnetic field associated with the device 282, followed by insonification of the delivery vehicles when appropriate via ultrasound emitted by the transducer 280 in response to signals from any of the implantable electronic circuits shown in
The frequency of the ultrasound from the therapeutic transducer can be varied to enhance or to reduce cavitation resulting from the ultrasound emitted from the transducer. Suppression of cavitation via frequency modulation is described in U.S. Pat. No. 5,694,936 entitled “Ultrasonic Apparatus For Thermotherapy With Variable Frequency For Suppressing Cavitation.” Methods for suppression or enhancement of cavitation are described in U.S. Pat. No. 4,689,986 entitled “Variable Frequency Gas-Bubble-Manipulating Apparatus And Method.” Enhancing cavitation to enhance sonodynamic activation, rupture of microspheres, microballoons or microbubbles, to locally heat tissue or to destroy tissue is possible by causing the frequency of the emitted ultrasound to decrease with time. On the other hand, cavitation may be decreased by causing the frequency of the emitted ultrasound to increase with time. This may be used to limit tissue damage while still supplying sufficient ultrasound to accomplish, e.g., a diagnostic purpose.
Sonodynamic activation of drugs or sonically-induced delivery vehicles rupture may occur at reduced power levels when properly-phased collinear acoustic signals at two different frequencies are provided. This effect has been shown to be particularly advantageous when one signal is at a frequency that is the second harmonic of the other signal and the two signals have an appropriate phase relationship. Increased tissue damage for a given intensity of ultrasound has also been reported by S. I. Umemura in Effect Of Second-Harmonic Phase On Producing Sonodynamic Tissue Damage, published in the 1996 IEEE Ultrasonics Symposium Proceedings, IEEE cat. no. 0-7803-3615-1/96, pp. 1313-1318. Sonochemical activation of a gallium-deuteroporphyrin complex (ATX-70) at reduced total power density by use of properly phased signals comprising a first signal and a second signal at twice the frequency of the first signal is described by S. I. Umemura et al. in Sonodynamic Approach To Tumor Treatment, published in the 1992 IEEE Ultrasonics Symposium Proceedings, IEEE cat. no. 1051-0117/92/0000-1231, pp. 1231-1240. An example of a transducer that is designed to provide for transduction of two ultrasonic signals, one of which may be the second harmonic of the other, is now described with reference to
In one embodiment, the diameter D is chosen to provide the desired fundamental transducer frequency via radial mode coupling, while the thickness TX is chosen to provide the second harmonic of the fundamental transducer frequency via thickness mode coupling. In this case, the diameter to thickness ratio D/TX may be approximately 2:1. Conventional mode charts provide more precise ratios for a variety of materials. The radial mode comprises radial particle motion primarily into and out from the center of the disc, i.e., perpendicular to the direction arrow 298, and symmetric about a cylindrical axis of the disc 292. The surfaces of the disc 292 exhibit longitudinal motion (i.e., parallel to the direction arrow 298) in response to the radial mode oscillation because of the Poisson's ratio of the material. The thickness mode comprises particle motion parallel to the direction arrow 298. As a result, acoustic energy propagating in the same direction at both frequencies may be coupled out of the disc 292 via the surfaces on which the electrodes 294 and 296 are formed. In some embodiments, the acoustic radiating surface emitting the ultrasound does not include an electrode 294 or 296. For example, electrodes may be disposed on the sidewalls, with ultrasound being emitted from the planar surfaces.
In another embodiment, the radial mode providing ultrasound at the fundamental transducer frequency may be chosen to be a harmonic of the lowest radial mode of the transducer 290. The transducer 290 may then be designed to have a larger diameter D than is possible when the lowest radial mode corresponds to the fundamental transducer frequency. This allows a larger area to be insonified by both ultrasonic signals than is otherwise feasible.
In one embodiment, frequencies of 500 kHz and 1 MHz are chosen as the two output frequencies for the dual frequency transducer 290. When the disc 292 comprises lead zirconium titanate (PZT), the diameter D is about 4 mm and the thickness TX is about 2 mm. The resulting dual frequency transducer 290 is small enough to be incorporated in an implantable device and yet also large enough to insonify a significant portion of the lumen of many blood vessels or stents.
In an alternative embodiment, a rectangular slab may be substituted for the disc 292. In one embodiment, a lateral mode may then be used instead of the radial mode associated with the disc 292 to provide the resonance at the fundamental frequency, with the thickness mode providing the resonance at the second harmonic. Conventional mode charts are used to select the ratios of the relevant dimensions.
Coating a cylindrical sidewall of the disc 292 and one of the electrodes 294 and 296 with an acoustic isolator 300 (analogous to the acoustic backing 194 of
Other types of localized therapy include coupling a thermally-activated medication to carrier molecules that have affinity to tumor tissue. Localized heating of the tumor tissue enables selective activation of the medication in the tumor tissue, as described in U.S. Pat. No. 5,490,840 entitled Targeted Thermal Release Of Drug-Polymer Conjugates. Localized heating may be effected through ultrasound via an ultrasonic transducer, e.g., transducers 44-46 (
When a suitable current, either AC or DC, is supplied via the leads 314, a magnetic field represented by flux lines 316 is generated. The magnetic field captures magnetic delivery vehicles that have been introduced into the patient's bloodstream. The increased concentration of delivery vehicles in the target vicinity can be used to provide local increases in delivery of drugs contained in the delivery vehicles.
Microbubbles including medication may be localized via a magnetic field and ruptured via an oscillating magnetic field as described in U.S. Pat. No. 4,652,257 entitled Magnetically-Localizable, Polymerized Lipid Vesicles And Method Of Disrupting Same. Suitable magnetic fields may be provided via application of RF or RF and DC electrical energy to the coil 312. In these embodiments, one or more of the transducers 44-46 of
Referring again to
In other embodiments, the coils 312 or 312A may form resistive heating transducers comprising a resistive material and may, if desired, be wound with bifilar wire to prevent them from acting as electromagnets or RF coupling coils. In another embodiment, the coils 312 or 312A may be heated directly by magnetic fields inducing current in the coils 312 or 312A, or, the body of the stent 310A may form a resistive heating transducer that is heated via magnetically-induced currents.
Stents are typically fashioned from metals that are biocompatible, such as titanium alloys (e.g., Nitinol, a nickel titanium alloy), stainless steel (e.g., 316L), platinum/iridium alloys or tantalum. All of these materials are suitable for fashioning a stent that is to be directly heated by RF-induced eddy currents (such stents would not include slots such as slot 118,
When a RF coupling coil is to be fashioned from these materials, those applications with higher power requirements may favor the materials with the lower resistivities.
When a current is passed through coils analogous to RF coupling coils 312 or 312A but comprising resistive material, or through a stent body as eddy currents, a local temperature rise is produced. This local temperature rise may be employed to rupture microbubbles having a melting point slightly above normal human body temperatures. One system using microbubbles having a controlled melting point to facilitate rupture of the microbubbles at predetermined localized areas within a patient's body is described, for example, in U.S. Pat. No. 4,558,690 entitled Method Of Administration Of Chemotherapy To Tumors. The localized heating may be provided by a structure similar to the cylindrical RF coupling coil 30A of
Transducers may be employed to facilitate drug penetration through the wall of a stent or stent graft and into the surrounding vasculature via sonophoresis, i.e., ultrasound enhancement of drug penetration into body tissues, or via iontophoresis, i.e., electrical field enhancement of drug penetration into body tissues, when suitable transducers are included in the stent or stent graft.
Methods and apparatus for localized drug delivery via sonophoresis or phonophoresis are described in U.S. Pat. No. 4,484,569 entitled Ultrasonic Diagnostic And Therapeutic Transducer Assembly And Method For Using, U.S. Pat. No. 5,016,615 entitled Local Application Of Medication With Ultrasound and U.S. Pat. No. 5,267,985 entitled Drug Delivery By Multiple Frequency Phonophoresis. These patents generally discuss transdermal delivery of medication to an affected area and note that use of more than one frequency of ultrasonic energy is beneficial in some situations.
An iontophoretic catheter for drug delivery is described in Iontophoretic Drug Delivery System, by R. G. Welsh et al., Semin. Intervent. Cardiol., No. 1, pp. 40-42 (1996). The system uses a microporous membrane enclosing a drug solution and a drug delivery electrode. A reference electrode is coupled to the biological tissue at a site that is separate from the drug delivery electrode. The reference and drug delivery electrodes are coupled to a power supply that provides an electrical potential between the two electrodes. Cationic drugs move from the anode towards the cathode, while anionic drugs move from the cathode towards the anode, with the rate being generally proportional to the current. Control over localized drug delivery is effected via control of the current and the duration of the current from the drug delivery electrode. One application is for delivery of antirestenotic agents.
Other uses of iontophoresis are described in U.S. Pat. No. 4,383,529 entitled Iontophoretic Electrode Device, Method and Gel Insert and U.S. Pat. No. 4,416,274 entitled Ion Mobility Limiting Iontophoretic Bioelectrode. These generally describe iontophoretic apparatus for localized transdermal drug delivery. Catheters adapted to provide localized iontophoretic drug delivery are described in U.S. Pat. No. 4,411,648 entitled Iontophoretic Catheter Device, and U.S. Pat. No. 5,499,971 entitled Method for Iontophoretically Delivering Drug Adjacent To A Heart. These discuss specific problems that are most readily addressed via localized drug delivery, including treatment of vascular regions to reduce restenosis following PTCA, drug delivery to tumor sites and techniques for iontophoretically delivering drugs in the vicinity of the heart without inducing arrhythmia due to electrical stimulation of heart muscles and nerves. In one embodiment, this is effected together with provision of electrical fields effective in providing drug transport by chopping a DC potential difference at a rate of between 5 and 15 kHz or by providing an asymmetric AC waveform that is in this frequency range. These techniques are necessary because the current being used for iontophoresis travels through a significant and somewhat unpredictable amount of body tissue that may well include muscles and nerves associated with the heart.
These concepts become more powerful when combined with the implantable transducers 44-46 of
A potential difference is established between the first 328 and second 330 electrodes by the implantable control IC 324 in response to signals coupled from outside the patient's body, via a RF coupling coil (not illustrated) as discussed above. The potential difference causes some types of drugs to migrate from one of the electrodes 328 and 330 towards the other, according to the polarity of the potential difference and the specific nature of the drug. This effect may be used to provide localized drug therapy, for example, to the wall of the vessel (not illustrated) into which the stent 322 is implanted. For example, systemically-administered drugs may be selectively transported from the blood into the vasculature surrounding a stent 322 to provide increased local concentrations of antistenotic agents.
One advantage of this technique is that the currents produced by the iontophoretic system 320 are extremely localized, i.e., are substantially confined to the area between the electrodes 328 and 330 and immediately surrounding tissues. This obviates some of the problems that have been encountered with iontophoretic systems that use a reference electrode that is placed at a body location remote from the drug delivery electrode, e.g., a catheterized drug delivery electrode used in conjunction with an externally-applied reference electrode. Accordingly, the iontophoretic system 320 may employ a DC voltage to effect iontophoretic drug delivery to parts of the body that cannot safely be treated via a catheterized system using DC for iontophoretic drug delivery. This is advantageous in improving the efficiency of drug delivery and in reducing exposure of other portions of the body to the electrical currents being employed for iontophoresis. One area where this may provide advantages, depending on stent placement and other factors, is in treating restenosis of cardiac blood vessels following stent insertion as a part of a PTCA treatment. A stent 322 intended for this purpose may also include sensors providing signals indicative of blood flow through the stent and therefore capable of providing data indicative of blockage as it develops. Additionally, the stent 322 including iontophoretic electrodes 328 and 330 may also be used to enhance localized delivery of drugs that are activated via therapeutic transducers coupled to the stent 322 or that are included in the vasculature upstream of the stent 322.
Another method for localized drug activation uses light supplied by an optical transducer, where the light is of the appropriate wavelength and intensity to break precursor molecules down into drugs. U.S. Pat. No. 5,445,608 entitled Method And Apparatus For Providing Light-Activated Therapy, describes a photodynamic therapy achieved by photoactivation of suitable optically active drugs. As described in this patent, the drugs are activated via catheterized light emitters inserted at the site to be treated and providing light at the wavelength required in order to activate the drugs and at the location where the activated drugs are needed for therapeutic purposes. Examples of precursor substances that can be optically activated by being broken down into drug molecules include long-chain cyanine dyes, dimers of phthalocyanine dyes and porphyrin compounds. A wide selection of solid state light sources including laser diodes and light emitting diodes is commercially available from a variety of vendors, including Motorola of Phoenix, Ariz. Laser diodes or light emitting diodes may be employed as transducers 44-46 in any of the systems shown in
The light emitting transducers 338 are coupled via lines 342 to an implantable control IC 344, which is in turn coupled to a RF coupling coil (not illustrated in
The transducers 44-46 of
An example of an application for the systems described above occurs in the situation where a stent is implanted to correct a stenosis or to repair an aneurysm in a blood vessel. Over time, tissue ingrowth at the ends of the stent can lead to stenosis, which can lead to thrombus formation. Thrombosis threatens the viability of the stent, and may require aggressive intervention using surgery or drugs. It is very undesirable to have to surgically resolve this situation if there is a viable alternative approach for relieving the blockage. One approach is to infuse the patient with thrombolytic drugs. This may lead to hemorrhagic consequences in other parts of the body, especially if the patient has, for example, recently had surgery. One approach to reducing the amount of thrombolytic drugs required to resolve thromboses in vitro is described in Prototype Therapeutic Ultrasound Emitting Catheter For Accelerating Thrombolysis, J. Ultrasound Med. 16, pp. 529-535 (1997). In this study, urokinase alone as a fibrinolytic agent was compared to urokinase in the presence of ultrasonic energy, with the latter showing marked improvement in the degree of fibrinolysis of artificial blood clots in glass tubes.
When, however, the stent includes a transducer, such as an ultrasonic transducer, coupled to the implantable electronic circuit of any of
Additionally, when flow or pressure sensors such as are described with respect to
Further, when stents are implanted to relieve stenosis, restenosis due to tissue ingrowth tends to occur within the first 6 months following angioplasty, with the greatest loss of luminal diameter occurring between the first and third month. Detection of tissue growth can be determined via pressure sensors as described above or via incorporation of the dielectric sensing filaments 234 and the implantable IC sensor 220B of
From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is to be understood broadly and is not limited except as by the appended claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4020830||Mar 12, 1975||May 3, 1977||The University Of Utah||Selective chemical sensitive FET transducers|
|US4218298||Nov 3, 1978||Aug 19, 1980||Kuraray Co., Ltd.||Selective chemical sensitive FET transducer|
|US4331654||Jun 13, 1980||May 25, 1982||Eli Lilly And Company||Magnetically-localizable, biodegradable lipid microspheres|
|US4383529||Nov 3, 1980||May 17, 1983||Wescor, Inc.||Iontophoretic electrode device, method and gel insert|
|US4411648||Jun 11, 1981||Oct 25, 1983||Board Of Regents, The University Of Texas System||Iontophoretic catheter device|
|US4416274||Feb 23, 1981||Nov 22, 1983||Motion Control, Inc.||Ion mobility limiting iontophoretic bioelectrode|
|US4484569||Mar 1, 1982||Nov 27, 1984||Riverside Research Institute||Ultrasonic diagnostic and therapeutic transducer assembly and method for using|
|US4558690||Jan 26, 1982||Dec 17, 1985||University Of Scranton||Method of administration of chemotherapy to tumors|
|US4652257||Mar 21, 1985||Mar 24, 1987||The United States Of America As Represented By The Secretary Of The Navy||Magnetically-localizable, polymerized lipid vesicles and method of disrupting same|
|US4681111 *||Apr 5, 1985||Jul 21, 1987||Siemens-Pacesetter, Inc.||Analog and digital telemetry system for an implantable device|
|US4689986||Mar 13, 1985||Sep 1, 1987||The University Of Michigan||Variable frequency gas-bubble-manipulating apparatus and method|
|US4799479 *||Jan 8, 1987||Jan 24, 1989||The Beth Israel Hospital Association||Method and apparatus for angioplasty|
|US4935345||Dec 30, 1987||Jun 19, 1990||Arizona Board Of Regents||Implantable microelectronic biochemical sensor incorporating thin film thermopile|
|US5016615||Feb 20, 1990||May 21, 1991||Riverside Research Institute||Local application of medication with ultrasound|
|US5267985||Feb 11, 1993||Dec 7, 1993||Trancell, Inc.||Drug delivery by multiple frequency phonophoresis|
|US5277191||Jun 19, 1991||Jan 11, 1994||Abbott Laboratories||Heated catheter for monitoring cardiac output|
|US5445608||Aug 16, 1993||Aug 29, 1995||James C. Chen||Method and apparatus for providing light-activated therapy|
|US5490840||Sep 26, 1994||Feb 13, 1996||General Electric Company||Targeted thermal release of drug-polymer conjugates|
|US5499971||Dec 14, 1993||Mar 19, 1996||Cortrak Medical, Inc.||Method for iontophoretically delivering drug adjacent to a heart|
|US5500013 *||Jan 13, 1995||Mar 19, 1996||Scimed Life Systems, Inc.||Biodegradable drug delivery vascular stent|
|US5523058 *||Sep 14, 1993||Jun 4, 1996||Hitachi, Ltd.||Ultrasonic irradiation apparatus and processing apparatus based thereon|
|US5694936||Sep 14, 1995||Dec 9, 1997||Kabushiki Kaisha Toshiba||Ultrasonic apparatus for thermotherapy with variable frequency for suppressing cavitation|
|US5749890 *||Dec 3, 1996||May 12, 1998||Shaknovich; Alexander||Method and system for stent placement in ostial lesions|
|US5749914 *||May 28, 1996||May 12, 1998||Advanced Coronary Intervention||Catheter for obstructed stent|
|US5807258||Oct 14, 1997||Sep 15, 1998||Cimochowski; George E.||Ultrasonic sensors for monitoring the condition of a vascular graft|
|US5810871||Apr 29, 1997||Sep 22, 1998||Medtronic, Inc.||Stent delivery system|
|US5833603||Mar 13, 1996||Nov 10, 1998||Lipomatrix, Inc.||Implantable biosensing transponder|
|US6053873 *||Apr 9, 1998||Apr 25, 2000||Biosense, Inc.||Pressure-sensing stent|
|US6190302 *||Nov 18, 1998||Feb 20, 2001||Hadasit Medical Research Services And Development Company Ltd.||Stereotactic radiotreatment and prevention of restenosis|
|US6210393 *||Dec 30, 1998||Apr 3, 2001||Pharmasonics, Inc.||Methods and systems for the inhibition of vascular hyperplasia|
|1||"Technical Report: Drug and Gene Delivery," ImaRX Pharmaceutical Corp., Jul. 1, 1997.|
|2||Andle, J.C. and J. F. Vetelino, "Acoustic Wave Biosensors," in IEEE Ultrasonics Symposium, Jun. 1995, pp. 451-460.|
|3||Erickson, Katherine A. and Peter Wilding, "Evaluation of a Novel Point-of-Care System, the i-STAT Portable Clinical Analyzer," Clinical Chem. 39(2):283-287, 1993.|
|4||Harrison et al., "Effect of Ultrasonic Exposure Time and Burst Frequency on the Enhancement of Chemotherapy by Low-Level Ultrasound," in IEEE Ultrasonics Symposium Proceedings, 1992, pp. 1245-1248.|
|5||Hetke et al., "Silicon Ribbon Cables for Chronically Implantable Microelectrode Arrays," IEEE Trans. Biomed. Eng., 41(4):314-321, Apr. 1994.|
|6||Jeffers et al., "Enhanced Cytotoxicity of Dimethylformamide by Ultrasound In Vitro," in IEEE Ultrasonics Symposium Proceedings, 1992, pp. 1241-1244.|
|7||Knutti et al., "Integrated Circuit Implantable Telemetry Systems," Eng. in Med. and Bio. Magazine, 2(1):47-50, Mar. 1983.|
|8||Pethig, R., Dielectric and Electronic Properties of Biological Materials, Wiley Press, Chichester, 1979, Chapter 7, "Biological Membranes and Tissue," pp. 207-243.|
|9||Shults et al., A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors, IEEE Trans. Biomed. Eng 41(10):937-942, Oct. 1994.|
|10||Tachibana, K. and Tachibana, S., "Prototype Therapeutic Ultrasound Emitting Catheter for Accelerating Thrombolysis," J. Ultrasound Med. 16:529-535, 1997.|
|11||Umemura et al., "Effect of Second-Harmonic Phase on Producing Sonodynamic Tissue Damage," in IEEE Ultrasonics Symposium Proceedings, vol. 2, San Antonio, Texas, Nov. 3-6, 1996, pp. 1313-1318.|
|12||Umemura et al., "Sonochemical Activation of Hematoporphyrin: A Potential Modality for Cancer Treatment," in Ultrasonics Symposium Proceedings, IEEE, 1989, pp. 955-960.|
|13||Umemura et al., "Sonodynamic Approach to Tumor Treatment," in IEEE Ultrasonics Symposium Proceedings, vol. 2, Tucson, AZ, Oct. 20-23, 1992, pp. 1231-1240.|
|14||Welsh et al., "Iontophoretic Drug Delivery System," Semin. Intervent. Cardiol. 1:40-42, 1996.|
|15||Wilensky, Robert L. and Keith L. March, "Microspheres," Semin. Intervent. Cardiol. 1:48-50, 1996.|
|16||Zierhofer, C.M. and E.S. Hochmair, "High-Efficiency Coupling-Insensitive Transcutaneous Power and Data Transmission Via an Inductive Link," IEEE Trans. Biomed. Eng., 37(7):716-722, Jul. 1990.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7966886 *||Oct 9, 2009||Jun 28, 2011||Cardiomems, Inc.||Method and apparatus for measuring pressure inside a fluid system|
|US8086296 *||Aug 27, 2007||Dec 27, 2011||Brainsonix Corporation||Methods for modifying electrical currents in neuronal circuits|
|US8702620 *||Nov 3, 2009||Apr 22, 2014||G.I. View Ltd.||Remote pressure sensing system and method thereof|
|US8771201 *||Jun 2, 2010||Jul 8, 2014||Vital Herd, Inc.||Health monitoring bolus|
|US8968204 *||Jun 12, 2007||Mar 3, 2015||Transonic Systems, Inc.||System and method of perivascular pressure and flow measurement|
|US9028415 *||Nov 8, 2006||May 12, 2015||Cook Medical Technologies Llc||Blood flow monitor with visual display|
|US9061133||Dec 27, 2012||Jun 23, 2015||Brainsonix Corporation||Focused ultrasonic transducer navigation system|
|US9072565 *||Jul 19, 2011||Jul 7, 2015||W & H Dentalwerk Burmoos Gmbh||Medical treatment device|
|US20080021325 *||Jun 12, 2007||Jan 24, 2008||Drost Cornelis J||System and method of perivascular pressure and flow measurement|
|US20080124373 *||Aug 2, 2007||May 29, 2008||Inframat Corporation||Lumen - supporting devices and methods of making and using|
|US20110295146 *||Nov 3, 2009||Dec 1, 2011||Gefen Ra Anan||Remote pressure sensing system and method thereof|
|US20110301437 *||Dec 8, 2011||Gabriel Karim M||Health monitoring bolus|
|US20120022393 *||Jan 26, 2012||Christian Pruckner||Medical treatment device|
|USRE42982 *||Feb 29, 2008||Nov 29, 2011||Mitchnick Mark A||Antimicrobial release system|
|WO2012045153A1 *||Oct 5, 2011||Apr 12, 2012||Satyapal Rathee||Image guided radiation therapy system and shielded radiofrequency detector coil for use therein|
|U.S. Classification||600/300, 600/549, 600/486, 600/505, 600/561|
|International Classification||A61F2/82, A61F2/07, A61N5/06, A61M1/36, A61N1/32, A61B5/00, A61B5/02, A61B8/06, A61M37/00, A61B5/05, A61B8/04, A61N1/30, A61F2/02|
|Cooperative Classification||A61B8/4483, A61B8/12, A61B8/06, A61B8/04, A61B5/14532, A61F2250/0001, A61N1/306, A61F2250/0002, A61M37/0092, A61F2002/072, A61N5/062, A61B2560/0219, A61F2/07, A61N1/325, A61B5/6862, A61M1/3656, A61B5/6876, A61F2/82, A61B5/0031, A61F2002/075, A61B8/56, A61N5/0601|
|European Classification||A61B5/68D2H, A61B5/68D1L, A61B5/00B9, A61B8/56, A61B8/06, A61M37/00U|
|Jan 30, 2007||AS||Assignment|
Owner name: CARDIOMETRIX, INC., WASHINGTON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VASCUSENSE, INC.;REEL/FRAME:018825/0305
Effective date: 20070126
Owner name: VASCUSENSE, INC., WASHINGTON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CIMOCHOWSKI, GEORGE E.;KEILMAN, GEORGE W.;REEL/FRAME:018825/0270
Effective date: 19981106
|Feb 11, 2010||AS||Assignment|
Owner name: PACESETTER, INC.,CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PACESETTER, INC.;CARDIOMETRIX, INC.;REEL/FRAME:023927/0373
Effective date: 20100112
Owner name: PACESETTER, INC.,CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARDIOMETRIX, INC.;REEL/FRAME:023927/0405
Effective date: 20100112
|Mar 23, 2012||FPAY||Fee payment|
Year of fee payment: 4